Immunohistochemistry (IHC); Used To Help Tell the Difference between Different Types of Cancer

Immunohistochemistry (IHC)
Immunohistochemistry (IHC)

Immunohistochemistry (IHC) is a method for detecting antigens or haptens in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. It is used in histology to detect the presence of a specific protein marker that can assist with accurate tumor classification and diagnosis. Immunohistochemistry uses antibodies to detect the location of proteins and other antigens in tissue sections. IHC is the most common application of immunostaining, a method used to detect a protein in a sample.

Immunohistochemistry is used to help diagnose diseases, such as cancer. Immunohistochemistry (IHC) Market can also be used to help tell the difference between different types of cancer. It is used to show whether or not the cancer cells have HER2 receptors and hormone receptors on their surface. IHC is a special staining process performed on fresh or frozen breast cancer tissue removed during biopsy. A positive test result means that the laboratory found a particular change in the proteins of tumor. This means that further genetic testing is needed.

Immunohistochemistry (IHC) is an important application of monoclonal as well as polyclonal antibodies to determine the tissue distribution of an antigen of interest in health and disease. IHC is widely used for diagnosis of cancers; specific tumor antigens are expressed de novo or up-regulated in certain cancers. Using specific tumor markers, physicians use IHC to diagnose if a tumor is benign or malignant, to determine its stage and grade, and to identify the cell type and origin of a metastasis in order to find the site of the primary tumor.

IHC help diagnose cancer, and thus, with the increasing prevalence of cancer across the globe, the use of immunohistochemistry is also increasing with a rapid pace, worldwide. For example, according to the American Cancer Society, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.

Comments

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market